Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML
Management of Cancer During Pregnancy: ASCO Guideline
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial
<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trial
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Contemporary Management of Acute Myeloid Leukemia
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Improving Collection and Analysis of Overall Survival Data
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Advancing drug development in myelodysplastic syndromes
Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study
Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With <i>FLT3</i>-ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
AML-591 Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
Molecular patterns identify distinct subclasses of myeloid neoplasia
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)